For investors
A defensible platform, real traction, a clear path.
ArrowBiome is a platform (not a product) with clinical proof, MIT-backed IP and commercial momentum, in a market migrating toward exactly what we make.
47 engagements / 19 markets
Including major global beauty multinationals and leading ingredient houses.
$29M revenue floor by 2029
Internal forecast $46M; EBITDA-positive in 2028; ~58% gross margin, on two products alone.
US$1.9M Pre-Series A
$950k secured; Series A ($8–12M) planned EOY 2026.
M&A exit logic
~75% of active-ingredient biotechs exit via M&A; comparable microbiome deals at 6–12× revenue.